---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-25-000027"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T12:34:01.128349+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q1 net loss narrows to $25.3M; Novo Nordisk license for LX9851, pipeline progress

## Summary
- Net loss of $25.3M ($0.07/sh) vs $48.4M ($0.20/sh) in Q1 2024; revenue $1.3M.
- Cash and investments $194.8M at Mar 31, 2025, down from $238.0M at Dec 31, 2024; includes $7.5M severance.
- Exclusive license to Novo Nordisk for LX9851; up to $1B milestones, $75M upfront/near-term payments plus royalties.
- Phase 2b PROGRESS study of pilavapadin (DPNP) met objective; 10 mg dose identified for Phase 3.
- Operating expenses down ~40% YoY as company transitions to R&D-focused.

## SEC filing metadata
- accession: 0001062822-25-000027
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000027/0001062822-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000027/lxrx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-25-000027
- JSON: https://secwatch.observer/filing/0001062822-25-000027.json
- Plain text: https://secwatch.observer/filing/0001062822-25-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.